InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non-Pharmaceutical Cannabinoid Sales

InMed Pharmaceuticals has announced an update regarding its BayMedica operations and outlined a strategic shift to prioritize its pharmaceutical development pipeline. The company stated that it will discontinue the commercialization of non-pharmaceutical cannabinoid products under BayMedica, citing a decision to focus resources on advancing its therapeutic programs. This move aligns with InMed’s broader strategy to concentrate on developing treatments for diseases with high unmet medical needs.

The company reported that the decision follows an evaluation of market conditions and operational priorities. By ceasing BayMedica’s commercial activities, InMed aims to allocate more resources toward its core pharmaceutical research and development efforts. The announcement also highlighted ongoing work in areas such as rare cannabinoids and their potential applications in treating dermatological and neurological conditions. InMed emphasized that this strategic realignment reflects its commitment to advancing clinical-stage programs while optimizing operational efficiency.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 6, 2026

Author

GOAI